Literature DB >> 21524717

Herpes simplex virus type 2 and cancer: a medical geography approach.

Frédéric Thomas1, Eric Elguero, Jacques Brodeur, Jerome Le Goff, Dorothée Missé.   

Abstract

Herpes simplex virus type-2 (HSV-2) has been identified as a possible aetiological agent of cancer in humans, especially prostate cancer, but results remain controversial. Here, we have addressed this question using a medical geography approach based on the national incidence of various cancers and seroprevalence of HSV-2 in 64 countries worldwide. We corrected reports of cancer incidence for national gross domestic product (GDP) because living in a wealthy nation likely increases the probability of having a cancer detected. Data were also corrected for latitude and diet. Our analysis not only confirms that prostate cancer and HSV-2 seroprevalence are positively associated, but it also reveals the existence of a positive relationship between HSV-2 and melanoma incidence in both men and women. These results, though correlational, suggest that HSV-2 should continue to be investigated as a possible oncogenic pathogen of humans.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21524717     DOI: 10.1016/j.meegid.2011.04.009

Source DB:  PubMed          Journal:  Infect Genet Evol        ISSN: 1567-1348            Impact factor:   3.342


  7 in total

1.  Incidence of adult brain cancers is higher in countries where the protozoan parasite Toxoplasma gondii is common.

Authors:  Frédéric Thomas; Kevin D Lafferty; Jacques Brodeur; Eric Elguero; Michel Gauthier-Clerc; Dorothée Missé
Journal:  Biol Lett       Date:  2011-07-27       Impact factor: 3.703

2.  Unpacking the 'black box' of total pathogen burden: is number or type of pathogens most predictive of all-cause mortality in the United States?

Authors:  A M Simanek; J B Dowd; A Zajacova; A E Aiello
Journal:  Epidemiol Infect       Date:  2014-12-18       Impact factor: 4.434

Review 3.  Molecular mechanisms of human herpes viruses inferring with host immune surveillance.

Authors:  Simon Jasinski-Bergner; Ofer Mandelboim; Barbara Seliger
Journal:  J Immunother Cancer       Date:  2020-07       Impact factor: 13.751

4.  Extensive CD4 and CD8 T Cell Cross-Reactivity between Alphaherpesviruses.

Authors:  Lichen Jing; Kerry J Laing; Lichun Dong; Ronnie M Russell; Russell S Barlow; Juergen G Haas; Meena S Ramchandani; Christine Johnston; Soren Buus; Alec J Redwood; Katie D White; Simon A Mallal; Elizabeth J Phillips; Christine M Posavad; Anna Wald; David M Koelle
Journal:  J Immunol       Date:  2016-01-25       Impact factor: 5.422

Review 5.  Berberine in Human Oncogenic Herpesvirus Infections and Their Linked Cancers.

Authors:  Miroslava Šudomová; Kateřina Berchová-Bímová; Stefania Marzocco; Alena Liskova; Peter Kubatka; Sherif T S Hassan
Journal:  Viruses       Date:  2021-05-28       Impact factor: 5.048

6.  Applying ecological and evolutionary theory to cancer: a long and winding road.

Authors:  Frédéric Thomas; Daniel Fisher; Philippe Fort; Jean-Pierre Marie; Simon Daoust; Benjamin Roche; Christoph Grunau; Céline Cosseau; Guillaume Mitta; Stephen Baghdiguian; François Rousset; Patrice Lassus; Eric Assenat; Damien Grégoire; Dorothée Missé; Alexander Lorz; Frédérique Billy; William Vainchenker; François Delhommeau; Serge Koscielny; Raphael Itzykson; Ruoping Tang; Fanny Fava; Annabelle Ballesta; Thomas Lepoutre; Liliana Krasinska; Vjekoslav Dulic; Peggy Raynaud; Philippe Blache; Corinne Quittau-Prevostel; Emmanuel Vignal; Hélène Trauchessec; Benoit Perthame; Jean Clairambault; Vitali Volpert; Eric Solary; Urszula Hibner; Michael E Hochberg
Journal:  Evol Appl       Date:  2012-11-16       Impact factor: 5.183

7.  Implication of human herpesviruses in oncogenesis through immune evasion and supression.

Authors:  Kenneth Alibek; Yeldar Baiken; Ainur Kakpenova; Assel Mussabekova; Samal Zhussupbekova; Madina Akan; Bolat Sultankulov
Journal:  Infect Agent Cancer       Date:  2014-01-20       Impact factor: 2.965

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.